a) the control of hypertension;
b) the management of angina pectoris;
c) long term management against re-infarction after recovery from acute myocardial infarction;
d) the control of most forms of cardiac dysrhythmias;
e) the prophylaxis of migraine;
f) the management of essential tremor;
g) relief of situational anxiety and generalised anxiety symptoms, particularly those of somatic type;
h) prophylaxis of upper gastrointestinal bleeding in patients with portal hypertension and oesophageal varices;
i) the adjunctive management of thyrotoxicosis and thyrotoxic crisis;
j) management of hypertrophic obstructive cardiomyopathy;
k) management of phaeochromocytoma peri-operatively (with an alpha-blocker).
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).
Efanesoctocog Alfa can be used for all age groups.
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).
Efanesoctocog Alfa can be used for all age groups.
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).
Efanesoctocog Alfa can be used for all age groups.
NOVACTAM is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below.
Skin and Skin Structure Infections caused by beta‑lactamase producing strains of Staphylococcus aureus, Escherichia coli,* Klebsiella spp.* (including K. pneumoniae*), Proteus mirabilis,* Bacteroides fragilis,* Enterobacter spp.,* and Acinetobacter calcoaceticus.*
Intra‑Abdominal Infections caused by beta‑lactamase producing strains of Escherichia coli, Klebsiella spp. (including K. pneumoniae*), Bacteroides spp. (including B. fragilis), and Enterobacter spp.*
Gynecological Infections caused by beta‑lactamase producing strains of Escherichia coli,* and Bacteroides spp.* (including B. fragilis*).
* Efficacy for this organism in this organ system was studied in fewer than 10 infections.
While NOVACTAM is indicated only for the conditions listed above, infections caused by ampicillin‑susceptible organisms are also amenable to treatment with NOVACTAM due to its ampicillin content. Therefore, mixed infections caused by ampicillin‑susceptible organisms and beta‑lactamase producing organisms susceptible to NOVACTAM should not require the addition of another antibacterial.
Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing infection and to determine their susceptibility to NOVACTAM.
This medicinal product is for diagnostic use.
Ultravist-240, -300, -370:
–Angiography, angiocardiography, digital subtraction angiography
–Contrast enhancement in computerised tomography
–Urography
–Visualization of body cavities
(Exception: myelography, ventriculography, cisternography)
Ultravist-300/-370:
Used in adult women for contrast-enhanced mammography to assess and detect known or suspicious lesions of the breast,
–in addition to mammography (with or without ultrasound) or
–as an alternative to magnetic resonance imaging (MRI) if MRI is contraindicated or not available.
First-Line Maintenance Treatment of Advanced Ovarian Cancer
Niraparib is indicated for the maintenance treatment of adult patients with
advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
- Maintenance Treatment of Recurrent Germline BRCA-mutated Ovarian Cancer
Niraparib is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAmut)
recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
A test is used by Your healthcare provider to determine whether you have BRCA mutated ovarian cancer
